• (919) 844 2494
  • FDA Warning Letters


    1. Warning Letter: Failure to validate software (ucm215449)

      Tags: | |

      In addition, FDA noted nonconformance with regards to section 501(h) of the Act, 21 U.S.C. 351(h), due to deficiencies of the Current Good Manufacturing Practice (CGMP) requirements of the Quality System (QS) regulation found at 21 C.F.R. Part at 21 C.F.R. Part 820. These deviations include, but are not limited to, the following:

      • Failure to validate the device software for the RTVue OCT with NDB, software versions 3.5 and 4.0 as required by 21 CFR 820.30(g). Specifically: “a. Software 3.5 Version C, was tested between [redacted]. The test result shows a failure with sequence [redacted]. The failure was identified as [redacted], unreasonable video baseline, known “bug”.
      • Verification and Validation for Version D was approved on [redacted] to address the test result identified from the testing of software Version Verification and Validation testing was performed on software 3.5 Version D, on [redacted]. The report identifies a “Remaining Defect List” and Number [redacted] is identified as “Critical”, “Spectrometer Motor Error!” This software version was released on [redacted] without addressing defect number [redacted] and without supporting documentation software defect number [redacted] was corrected.
      • Verification and Validation test results/raw data for software 4.0, Version B, were performed on [redacted] and [redacted]. Sections of the test data were not performed, unsigned, and/or missing as follows: I. Section 16 – Cornea Module, not performed. II. Section 11 – Gridline Examine and Analyze, not performed. III. Section 10.2 – Verify [redacted] new function, unsigned and undated. IV. Section 15 – Combined Progression of [redacted] and [redacted] scans, a test sequence was not performed. V. Unidentified Section, raw test data missing. This test section is signed-off by an employee, with a completion date of [redacted].
      •  Electronic sign-off copy of the Verification and Validation Report for software 4.0, Version B. found the following: I. Section 16 – all sequence is entered as pass without supporting data to demonstrate the test was performed. II. Section 11 – all sequence entered as pass without supporting data to demonstrate the test was performed. III. Section 10.2 – contains an electronic signature of an employee, dated [redacted] IV. Section 15 – all sequence entered as pass without supporting data to demonstrate the test was performed. V. Section 3.1 – Verify Calibration Data is entered as being completed on [redacted] There is no supporting data to demonstrate sequence testing was performed. However, the last sequence test page of this test section is identical to a test performed by an employee on [redacted], not [redacted] as entered into the firm’s electronic sign-off copy.
      • Verification and Validation report for software version 2.0 is not available for review. According to your employee, once the results are entered into your electronic report, the raw tests data are discarded. Therefore, you have no evidence the sequence testing was performed.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    2. Warning Letter: No Procedures for Controlling Worksheets (ucm218221)

      Tags: | |

      Your firm has no procedures for controlling laboratory worksheets including changes to worksheets, issuance of laboratory worksheets, and reconciliation of laboratory worksheets. The worksheet “Internal Communication – Batch Release Information” by the warehouse, which is used to identify released product, was created after [redacted] documented release of finished product for Heparin I.V. Flush Syringes and Normal Saline I.V. Flush Syringes prior to obtaining media fill results. This sheet is used to communicate batch release information to warehouse operations. Use of this sheet is not documented in any Medefil procedure nor is control over this sheet documented.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    3. Warning Letter: Failure to establish procedures (ucm216937)

      Tags: | |

      Failure to establish and maintain adequate procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example, your firm opened CAPAs in response to quality audit data which showed the lack of QS regulation training in many departments within your firm. However, the CAPAs do not contain or reference documentation to support complete implementation of the CAPA activities, such as investigating the cause of the nonconformity, identifying the action needed to correct and prevent recurrence, and verification or validation of the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device, as defined in your firm’s Corrective & Preventive Action Procedure QSR-115.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    4. Warning Letter: Failed to validate input/output (ucm214564)

      Tags: | |

      Your firm failed to check the accuracy of the input to and output from the computer or related systems of formulas or other records or data and establish the degree and frequency of input/output verifications. For example, the performance qualification of your [redacted] system software (Validation No. 4000-03-PQ-0002) failed to include verification of the expiration date calculations in the [redacted] system. In addition, there is no established degree and frequency of performing the verification. Discrepancy reports have documented that product labeling with incorrect expiration dates have been created and issued for use.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    5. Warning Letter: Uncontrolled spreadsheets (ucm227896)

      Tags: | |

      Your firm has failed to exercise appropriate controls over computer or related systems to assure that changes in master production and control records, or other records, are instituted only by authorized personnel [21 C.F.R § 211.68(b)].

      • Your firm’s laboratory analysts have the ability to access and delete raw chromatographic data located on the [redacted] of [redacted] used to conduct HPLC testing. Due to this unrestrictive access, there is no assurance that laboratory records and raw data are accurate and valid.
      • Your firm’s laboratory analysts have the ability to access and modify the  formulas in the Excel spreadsheets  used to calculate assay results for Guaifenesin and [redacted] drug products. Due to this unrestricted access, there is  no assurance that the formulas in the Excel spreadsheets are accurate and valid.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    6. Warning Letter: Failure to document validation (ucm201895)

      Tags: | |

      Failure to maintain a design history file for the “Defender” air filtration system, as required by 21 CFR § 820.300). Specifically, your firm  could not locate the design inputs, outputs, verification and validation documents, design reviews and design changes for the “Defender”.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    7. Warning Letter: Failure to validate CAPA proedures (ucm201897)

      Tags: | |

      Your firm’s Corrective and Preventive Action Practice form does not specify that you will verify or validate the corrective and preventive action to ensure that such action is effective and does not adversely affect the finished device as required by 21 CFR § 820.100(a)(4). For example, your firm needs to perform effectiveness checks in order to verify that the corrective and preventive actions were effective  as to the intended purpose of the action and that new issues or concerns are not introduced.
      Failure to establish and maintain procedures for the identification, documentation, validation or where appropriate verification, review, and approval of design changes before their implementation as required by 21 CFR § 820.30(i). Specifically, your firm has failed to establish and maintain design control procedures for the design changes that were made to your devices during the months of May and June of 2009.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    8. Warning Letter: Failure to maintain adequate procedures (ucm200878)

      Tags: | |

      Failure to establish and maintain adequate procedures to identify all the action(s) needed to correct and prevent the recurrence of nonconforming products and other quality problems, as required by 21 CFR 820.100(a)(3). For example: You have decided to issue a software update as a corrective measure for resistor related issues. However, our review indicates that the latest software update is only a method of detection and will not prevent resistor failures.  “Failure to review and evaluate all complaints to determine whether an investigation is necessary and maintain a record that includes the reason when no investigation was made, as required by 21 CFR 820.198(b).

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    9. Warning Letter: Failure of adequate controls (ucm200384)

      Tags: |

      Failure to have adequate controls to prevent manipulation of raw data during routine analytical testing. “For example, your firm’s laboratory analyst had modified printed raw data related to the IR Spectra test of [redacted] and [redacted]. We are concerned that the lack of security or system controls allows for this practice.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>

    10. Warning Letter: Incomplete design validation (ucm200389)

      Tags: | |

      Design validation failed to include testing of production units under actual or simulated use conditions as required by 21 C.F.R. 820.30(g). For example, the MedStar System design history records do not include documentation to demonstrate that the physiological data (e.g. blood pressure and heart rate readings) obtained from the patient is the identical data transmitted from the MedStar Collection Server.

      View the original warning letter.


      Recommended Solutions

      Compliance Training >>

      Recommended Solutions

      ExcelSafe >>

      Recommended Solutions

      Ofni Clinical >>

      Recommended Solutions

      Part 11 Toolkit >>

      Recommended Solutions

      Part 11 Advisor >>

      Recommended Solutions

      MedWatch Reporter >>

      Recommended Solutions

      Computer Validation >>

      Recommended Solutions

      Custom Programming >>

      Recommended Solutions

      Validating MS Excel Spreadsheets >>

      Recommended Solutions

      Access Databases >>